Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic

Clinical and Vaccine Immunology

Volumn 21, Issue 10, 2014, Pages 1452-1459

  Shaughnessy, Jutamas ^a   Vu, David M ^b   Punjabi, Rahi ^a   Serra Pladevall, Judit ^a   De Oliveira, Rosane B ^a   Granoff, Dan M ^b   Ram, Sanjay ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FACTOR H 6,7 HUMAN IGG1 FC FUSION PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; COMPLEMENT; COMPLEMENT FACTOR H; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HUMAN; IN VIVO STUDY; INFANT; INFECTION PREVENTION; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; RAT; ANIMAL; BACTERIAL COUNT; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MENINGOCOCCAL INFECTIONS; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD; COLONY COUNT, MICROBIAL; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MENINGOCOCCAL INFECTIONS; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS, SEROGROUP C; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84907484193     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00444-14     Document Type: Article

References (36)

1. Anonymous. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
2. Ram S, Lewis LA, Rice PA. 2010. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23:740-780. http://dx.doi.org/10.1128/CMR.00048-09.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797. http://dx.doi.org/10.1038/ni.1923.
4. Blom AM, Hallstrom T, Riesbeck K. 2009. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol. Immunol. 46:2808-2817. http://dx.doi.org/10.1016/j.molimm.2009.04.025.
5. Kraiczy P, Wurzner R. 2006. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43:31-44. http://dx.doi.org/10.1016/j.molimm.2005.06.016.
6. Ferreira VP, Pangburn MK, Cortes C. 2010. Complement control protein factor H: the good, the bad, and the inadequate. Mol. Immunol. 47:2187-2197. http://dx.doi.org/10.1016/j.molimm.2010.05.007.
7. Ripoche J, Day AJ, Harris TJ, Sim RB. 1988. The complete amino acid sequence of human complement factor H. Biochem. J. 249:593-602.
8. Kuhn S, Zipfel PF. 1996. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur. J. Immunol. 26:2383-2387. http://dx.doi.org/10.1002/eji.1830 261017.
9. Sharma AK, Pangburn MK. 1996. Identification of three physically and functionally distinct binding sites for C3b in human complement factorH by deletion mutagenesis. Proc. Natl. Acad. Sci. U. S. A. 93:10996-11001. http://dx.doi.org/10.1073/pnas.93.20.10996.
10. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10:728-733. http://dx.doi.org/10.1038/ni.1755.
11. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D, Barlow PN, Pangburn MK, Kavanagh D. 2009. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J. Immunol. 182:7009-7018. http://dx.doi.org/10.4049/jimmunol.0804031.
12. Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS. 2011. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. U. S. A. 108:2897-2902. http://dx.doi.org/10.1073/pnas.1017087108.
13. Pangburn MK. 2002. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J. Immunol. 169:4702-4706. http://dx.doi.org/10.4049/jimmunol.169.9.4702.
14. Pangburn MK, Ferreira VP, Cortes C. 2008. Discrimination between host and pathogens by the complement system. Vaccine 26(Suppl 8):I15-I21. http://dx.doi.org/10.1016/j.vaccine.2008.11.023.
15. Frasch C, Zollinger W, Poolman J. 1985. Proposed schema for identification of serotypes of Neisseria meningitidis, p 519-524. In Schoolnik G (ed), The pathogenic neisseriae. American Society for Microbiology, Washington, DC.
16. Pastor P, Medley FB, Murphy TV. 2000. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr. Infect. Dis. J. 19:324-328. http://dx.doi.org/10.1097/00006454-200004000 -00012.
17. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4:e00339-13. http://dx.doi.org.10.1128/mBio.00339-13.
18. Shaughnessy J, Ram S, Bhattacharjee A, Pedrosa J, Tran C, Horvath G, Monks B, Visintin A, Jokiranta TS, Rice PA. 2011. Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J. Biol. Chem. 286:22235-22242. http://dx.doi.org/10.1074/jbc.M111.225516.
19. Ray TD, Lewis LA, Gulati S, Rice PA, Ram S. 2011. Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H. 8 and Laz lipoproteins. J. Immunol. 186:4881-4894. http://dx.doi.org/10.4049/jimmunol.1003623.
20. Lewis LA, Vu DM, Granoff DM, Ram S. 2014. Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect. Immun. 82:2574-2584. http://dx.doi.org/10.1128/IAI.01517-14.
21. Gulati S, Agarwal S, Vasudhev S, Rice PA, Ram S. 2012. Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J. Immunol. 188:3416-3425. http://dx.doi.org/10.4049/jimmunol.1102746.
22. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027. http://dx.doi.org/10.1371/journal.ppat.1001027.
23. Harris SL, King WJ, Ferris W, Granoff DM. 2003. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect. Immun. 71: 275-286. http://dx.doi.org/10.1128/IAI.71.1.275-286.2003.
24. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893. http://dx.doi.org/10.1038/nature07769.
25. Shaughnessy J, Lewis LA, Jarva H, Ram S. 2009. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77:2094-2103. http://dx.doi.org/10.1128/IAI.01561-08.
26. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, Lyon M, Uhrin D, Barlow PN. 2008. A new map of glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 181:2610-2619. http://dx.doi.org/10.4049/jimmunol.181.4.2610.
27. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606-5615. http://dx.doi.org/10.4049/jimmunol.172.9.5606.
28. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
29. Agarwal S, Specht CA, Haibin H, Ostroff GR, Ram S, Rice PA, Levitz SM. 2011. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2:e00178-11. http://dx.doi.org/10.1128/mBio.00178-11.
30. Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, Brade V, Kraiczy P, Noris M, Remuzzi G. 2002. Factor H family proteins: on complement, microbes and human diseases. Biochem. Soc. Trans. 30:971-978.
31. Ingwer I, Petersen BH, Brooks G. 1978. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. J. Lab. Clin. Med. 92:211-220.
32. Kahler CM, Martin LE, Shih GC, Rahman MM, Carlson RW, Stephens DS. 1998. The (alpha28)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect. Immun. 66:5939-5947.
33. Lewis LA, Choudhury B, Balthazar JT, Martin LE, Ram S, Rice PA, Stephens DS, Carlson R, Shafer WM. 2009. Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect. Immun. 77:1112-1120. http://dx.doi.org/10.1128/IAI.01280-08.
34. Ram S, Lewis LA, Agarwal S. 2011. Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement. J. Biol. Chem. 286:8297-8307. http://dx.doi.org/10.1074/jbc.M110.184838.
35. Massari P, Ram S, Macleod H, Wetzler LM. 2003. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol. 11:87-93. http://dx.doi.org/10.1016/S0966-842X(02)00037-9.
36. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.